SE0401069D0 - Use of Compounds for the Treatment of Diseases and Conditions - Google Patents

Use of Compounds for the Treatment of Diseases and Conditions

Info

Publication number
SE0401069D0
SE0401069D0 SE0401069A SE0401069A SE0401069D0 SE 0401069 D0 SE0401069 D0 SE 0401069D0 SE 0401069 A SE0401069 A SE 0401069A SE 0401069 A SE0401069 A SE 0401069A SE 0401069 D0 SE0401069 D0 SE 0401069D0
Authority
SE
Sweden
Prior art keywords
diseases
compounds
treatment
conditions
administrated
Prior art date
Application number
SE0401069A
Other languages
English (en)
Inventor
Anders Aspberg
Dick Heinegaard
Anna Johnson
Alexander Kvist
Original Assignee
Anamar Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anamar Medical Ab filed Critical Anamar Medical Ab
Priority to SE0401069A priority Critical patent/SE0401069D0/sv
Publication of SE0401069D0 publication Critical patent/SE0401069D0/sv
Priority to ES05735125T priority patent/ES2409343T3/es
Priority to JP2007510653A priority patent/JP2007534749A/ja
Priority to AU2005235171A priority patent/AU2005235171B2/en
Priority to PCT/SE2005/000599 priority patent/WO2005102362A1/en
Priority to EP05735125A priority patent/EP1747007B1/en
Priority to NZ550893A priority patent/NZ550893A/en
Priority to US11/587,675 priority patent/US7956047B2/en
Priority to CA2564436A priority patent/CA2564436C/en
Priority to ZA2006/08926A priority patent/ZA200608926B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0401069A 2004-04-26 2004-04-26 Use of Compounds for the Treatment of Diseases and Conditions SE0401069D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0401069A SE0401069D0 (sv) 2004-04-26 2004-04-26 Use of Compounds for the Treatment of Diseases and Conditions
ES05735125T ES2409343T3 (es) 2004-04-26 2005-04-26 Uso de sulfato de condroitina E (SC-E) para el tratamiento de enfermedades o afecciones relacionadas con la formación de fibrillas de colágeno
JP2007510653A JP2007534749A (ja) 2004-04-26 2005-04-26 コラーゲン原線維形成に関連する疾患または状態の治療のためのコンドロイチン硫酸（ｃｓ−ｅ）の使用
AU2005235171A AU2005235171B2 (en) 2004-04-26 2005-04-26 Use of chondroitin sulphate E (CS-E) for the treatment diseases or conditions related to collagen fibril formation.
PCT/SE2005/000599 WO2005102362A1 (en) 2004-04-26 2005-04-26 Use of chondroitin sulphate e (cs-e ) for the treatment diseases or conditions related to collagen fibril formation.
EP05735125A EP1747007B1 (en) 2004-04-26 2005-04-26 Use of chondroitin sulphate e (cs-e ) for the treatment diseases or conditions related to collagen fibril formation.
NZ550893A NZ550893A (en) 2004-04-26 2005-04-26 Use of chondroitin sulphate E (CS-E) for the treatment of diseases or conditions related to collagen fibril formation
US11/587,675 US7956047B2 (en) 2004-04-26 2005-04-26 Use of chondroitin sulphate E (CS-E) for the treatment of diseases or conditions related to collagen fibril formation
CA2564436A CA2564436C (en) 2004-04-26 2005-04-26 Use of chondroitin sulphate e (cs-e ) for the treatment of disease or conditions related to collagen fibril formation.
ZA2006/08926A ZA200608926B (en) 2004-04-26 2006-10-26 Use of chondroitin sulphate e (cs-e) for the treatment of diseases or conditions related to collagen fibril formation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401069A SE0401069D0 (sv) 2004-04-26 2004-04-26 Use of Compounds for the Treatment of Diseases and Conditions

Publications (1)

Publication Number Publication Date
SE0401069D0 true SE0401069D0 (sv) 2004-04-26

Family

ID=32322669

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401069A SE0401069D0 (sv) 2004-04-26 2004-04-26 Use of Compounds for the Treatment of Diseases and Conditions

Country Status (10)

Country Link
US (1) US7956047B2 (sv)
EP (1) EP1747007B1 (sv)
JP (1) JP2007534749A (sv)
AU (1) AU2005235171B2 (sv)
CA (1) CA2564436C (sv)
ES (1) ES2409343T3 (sv)
NZ (1) NZ550893A (sv)
SE (1) SE0401069D0 (sv)
WO (1) WO2005102362A1 (sv)
ZA (1) ZA200608926B (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401069D0 (sv) 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions
JP2008195705A (ja) * 2007-01-15 2008-08-28 Daiichi Sankyo Healthcare Co Ltd ロキソプロフェン含有経口用組成物
JPWO2008102568A1 (ja) * 2007-02-22 2010-05-27 株式会社Ｐｇリサーチ 骨軟骨形成促進剤
GB201001203D0 (en) 2010-01-25 2010-03-10 Anamar Medical Ab Use of pharmaceutically active compounds
JP2012031122A (ja) * 2010-08-02 2012-02-16 Kracie Home Products Ltd コラーゲン産生促進剤
CN108727492B (zh) * 2017-04-20 2021-07-13 广州文瑞生物科技有限公司 抗胶原蛋白vi全人抗体消退动脉粥样硬化的免疫治疗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503951A (ja) * 1988-12-20 1992-07-16 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション 創傷治癒に活性のあるポリペプチド―ポリマー複合体
WO1991015216A1 (en) * 1990-04-05 1991-10-17 Kennedy Thomas P Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
JPH10120577A (ja) 1996-10-16 1998-05-12 Sekisui Chem Co Ltd 創傷治療剤
US5929050A (en) 1998-02-27 1999-07-27 Petito; George D. Chondroitin sulfate composition and method for wound treatment
FR2791262B1 (fr) * 1999-03-22 2001-09-28 Virbac Sa Compositions a base de chondroitine et de chitosan pour la protection, le traitement ou le remplacement des tissus conjonctifs
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
EP1292314A2 (en) 2000-05-23 2003-03-19 The Trustees of Columbia University in the City of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans
JP2002080371A (ja) * 2000-06-23 2002-03-19 Seikagaku Kogyo Co Ltd プラスミノーゲンアクチベーター活性促進剤
ES2381935T3 (es) * 2000-10-16 2012-06-01 Genentech, Inc. Polipéptidos WISP y sus aplicaciones terapéuticas
RU2216332C1 (ru) 2002-02-18 2003-11-20 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лечебный препарат для лечения артроза
JP2004059506A (ja) * 2002-07-29 2004-02-26 Taisho Pharmaceut Co Ltd セレクチン及びケモカインに作用する過硫酸化オリゴ糖
JP4567942B2 (ja) * 2002-12-27 2010-10-27 生化学工業株式会社 破骨細胞形成抑制剤
SE0401069D0 (sv) * 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions

Also Published As

Publication number Publication date
WO2005102362A1 (en) 2005-11-03
EP1747007B1 (en) 2013-03-20
AU2005235171A1 (en) 2005-11-03
CA2564436A1 (en) 2005-11-03
JP2007534749A (ja) 2007-11-29
AU2005235171A2 (en) 2005-11-03
CA2564436C (en) 2014-06-17
AU2005235171B2 (en) 2010-11-11
NZ550893A (en) 2010-07-30
ES2409343T3 (es) 2013-06-26
WO2005102362A8 (en) 2006-06-22
ZA200608926B (en) 2008-04-30
EP1747007A1 (en) 2007-01-31
US7956047B2 (en) 2011-06-07
US20080200426A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
NO20080068L (no) Topisk unguale formuleringer
EA200702253A1 (ru) Фармацевтическая композиция
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
CY1105721T1 (el) Δερματικοι αναισθητικοι παραγοντες
EA201000329A1 (ru) Циклические депсипептиды
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
NO20075368L (no) Antiinflammatoriske modaliteter
CY1116840T1 (el) Χρηση 24-norudca
WO2005102362A8 (en) Use of chondroitin sulphate e (cs-e ) for the treatment diseases or conditions related to collagen fibril formation.
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ATE427315T1 (de) Neue makrolide
ATE432275T1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
TR201901268T4 (tr) Mezenkimal kök hücreleri ve bunların kullanımları.
ATE474574T1 (de) Imidazoazephinonverbindungen
EA200970816A1 (ru) Новая лекарственная форма